Agios Pharmaceuticals to Present at the Leerink Swann 2013 Global Healthcare Conference
Cambridge, Mass. – February 6, 2013 – Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the Leerink Swann 2013 Global Healthcare Conference on Wednesday, February 13, 2013 at 3:00PM EST at the Waldorf Astoria Hotel in New York City.
Dr. Schenkein is expected to discuss the company’s portfolio of cancer metabolism therapeutics, its expansion into targeting inborn errors of metabolism, and the assets and capabilities that position Agios as a leader in dysregulated metabolism.
About Agios Pharmaceuticals, Inc.
Agios is the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic. All Agios programs focus on genetically identified patient populations leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.
